|
|
|
Summary
of 2001 CPCRA Posters and Presentations
| 41st Interscience
Conference on Antimicrobial Agents and Chemotherapy (ICAAC),
December 16-19, 2001, Chicago, IL |
Vazquez
J, Peng G, Sobel J, Steele-Moore L, Schuman P, Holloway W. Dynamic
evolution of the in-vitro antifungal sucsceptibility of Candida
species recovered from HIV-infected women receiving fluconazole
| 1st IAS Conference
on HIV Pathogenesis and Treatment, July 8-11, 2001 in Buenos
Aires, Argentina |
Mayers
D, Merigan T, Wentworth D, Neaton J, Hoover M, Hoetelmans R, Verbiest
W, Baxter J. Both Antiviral Drug Levels and Drug Resistance Are Associated With Short-Term Virologic Responses to Subsequent Drug Regimens in CPCRA 046 (GART). Poster, Abstract Number: 124
MacArthur
R. Baseline Characteristics of 725 HIV+ Antiretroviral Naïve Persons
Enrolled in a Multicenter Antiretroviral Strategy Trial. Poster, Abstract Number 295.
Tedaldi
E, Huppler Hullsiek K, Malvestutto C, Arduino R, Fisher E, Gaglio
P, Jenny-Avital E, McGowan J, Perez G. Prevalence and Characteristics
of HCV Coinfection in a Community Based HIV Clinical Trials Group. Poster, Abstract Number: 545.
Kostman
J, Luskin-Hawk R, Wentworth D, Bartsch G, Malvestutto C, Abrams
D. Characteristics of Patients Who Choose to Remain Antiretroviral-Naive
and Those Who Begin Antiretroviral Therapy. Poster, Abstract Number: 294.
Friedland
G. Duration of Antiretroviral Adherence Predicts Biologic Outcomes
in Clinical Trials. Oral, Abstract Number: 33.
| 5th International
Workshop on HIV Drug Resistance and Treatment Strategies,
June 4-8, 2001 |
Hoover
M, Mayers D, Wentworth D, Neaton J, Hertogs K, Verbiest W. NNRTI Phenotypic
and Genotypic Resistance in Patients With Virologic Failure During
Salvage Therapy - 12 Week Outcome Data from the GART Study (CPCRA
046). Poster, Abstract Number: 105
Mayers
D, Merigan T, Wentworth D, Neaton J, Hoover M Hoetelmans R, Piscitelli
S, Verbiest, W, Baxter J. Both Drug Resistance and Antiretroviral
Drug Levels are Associated with Short-Term Virologic Responses to
Subsequent Drug Regimens in CPCRA 046 (GART Study). Poster, Abstract Number 87.
| 22nd Annual
Meeting of the Society for Clinical Trials, May 19-23, 2001 |
Chen
L, Neaton J, Louis T. Defining Multiple Endpoints in AIDS Clinical
Trials. Poster, Abstract Number: P26.
| 2nd Clinical
Pharmacology Symposium, April 2-4, 2001 |
Mayers D, Merigan T, Wentworth D, Neaton J, Hoover M, Hoetelmans
R, Piscitelli S, Verbiest, W, Baxter J. Both Antiretroviral Drug Levels and Drug Resistance are Associated with Short-Term Virologic Responses to Subsequent Drug Regimens in CPCRA 046 (GART Study)
| 8th Conference
on Retroviruses and Opportunistic Infections, February 4-8,
2001, Chicago, IL |
Mannheimer
S, Friedland G, Matts J, Child C, Chesney M. CPCRA 057 and CPCRA
058 - Antiretroviral Adherence Correlates with Quality of Life. Poster, Abstract Number: 485.
Markowitz
N, Bebchuk J, Denning E, Abrams D. Prediction of CD4+ Cell Response
to Subcutaneous Recombinant Interleukin-2 (SC rIL-2). Poster, Abstract Number: 343.
MacArthur
R, Perez G, Walmsley S, Baxter J, Neaton J, Wentworth D. CD4+ Cell
Count is a Better Predictor of Disease Progression than HIV RNA
Level in Persons with Advanced HIV Infection on Highly Active Antiretroviral
Therapy. Poster, Abstract Number: 203.
|
|
